TeamDrive
RUS

Japan saved $12.2 billion through use of generics

12 March 2018

GMP News

Japan’s Ministry of Health, Labour and Welfare (MHLW) suggested that the country’s push to lower prescription costs by switching to generic drugs is forecast to have saved $12.2 billion in fiscal 2017.

The reduction is about 40 percent larger than the savings estimated for fiscal 2015. In 2015, the MHLW unveiled a plan to boost the competitiveness of the country’s pharmaceutical industry, with the government aiming to increase the share of generic drugs used to at least 80 percent by 2020, compared to 46.9 percent in 2013. According to the latest figures from the health ministry, as of the end of September 2017, the share of generic drugs was 65.8 percent.

The move to increase the use of generic drugs is one of a number of measures introduced in Japan to curb rising health care spending, with the government announcing at the end of 2016 plans to review drug prices annually instead of once every two years, with the review to include all prescription medicines.


Previous publication Next publication

Media Center

  • 19 September 2018

    Russia approves new state strategy for pharmaceutical industry

    A new state strategy for the development of the domestic pharmaceutical industry, known as "Strategy for the development of the pharmaceutical industry of Russia until 2030," has been recently approved by the Russian Ministry of Industry and Trade, with the aim to bring the Russian pharmaceutical production to a new level.

  • 18 September 2018

    The Ministry of Health of the Russian Federation improves patent protection law

    The Ministry of Health of Russia has published a notification on the development of amendments to Federal Law No. 61 of 12.04.2010 “On circulation of medicinal products”, designed to synchronize it with regulatory acts of the Eurasian Economic Union. The procedure for registration of the medicinal product will be corrected.

  • 17 September 2018

    GlobalData published new report on the Top 25 pharma companies

    The performance highlights of the Top 25 publicly traded global pharmaceutical companies by Market Cap (Mcap) for the quarter ended June 30, 2018 (Q2), compared to the quarter ended March 31, 2018 (Q1), have been analyzed in the latest research from GlobalData, a leading data and analytics company.

  • 14 September 2018

    US scientists conduct clinical trial of influenza vaccine with imiquimod

    A Phase 1 clinical trial examining whether a topical cream can enhance the immune response conferred by a “pre-pandemic” influenza vaccine is underway at Baylor College of Medicine in Houston (USA). Investigators are evaluating whether imiquimod cream, which is commonly used to treat genital warts and certain skin cancers, can boost the body’s immune response to an H5N1 influenza vaccine. The trial is enrolling 50 healthy adults ages 18-50 years. 

Read more